Clinical trial readout dates for Zai Lab Limited, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.
| Phase 3 ZL-1109 (VRDN-003) Thyroid Eye Disease (TED) · NCT07211776 | March 2027 Ongoing |
| Phase 1/2 ZL-1310 Solid Tumors · NCT06885281 | August 2027 Recruiting |
| Phase 3 ZL-1310 Small-cell Lung Cancer · NCT07218146 | June 2028 Recruiting |
| Phase 3 ZL-1310 in combination with Atezolizumab or Durvalumab Extensive-Stage Small Cell Lung Cancer · NCT07796100 | June 2030 Not Yet Recruiting |
Zai Lab Limited reported $560M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $46M; at that rate the cash would last about 12 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-05 |
| 8-K Other Events — often topline trial data | 2026-10-23 |